newsfilter
← Latest News
GlobeNewswire·

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update

  • NRx Pharmaceuticals, Inc. will release its third quarter 2026 financial results before the market opens on Tuesday, November 17, 2026.
  • The company will host a conference call at 8:00 am ET on November 17, 2026, with a live webcast available on its investor relations website.
  • Conference call participants can join via webcast or by dialing 1-800-717-1738 domestically or +1-646-307-1865 internationally.
  • NRx Pharmaceuticals holds an Abbreviated New Drug Approval (ANDA) for Preservative-Free Ketamine.
  • The company is seeking New Drug Approval for intravenous ketamine (NRX-100) with claims for treating depression and suicidality.
  • NRX-100 has received Fast Track Designation for treating suicidal ideation in depression, including bipolar depression.
  • In October 2026, the Defense Advanced Research Projects Agency awarded NRx an $11.25 million contract for a phase 3 trial of NRX-101.
  • NRX-101 is an oral drug combination of D-cycloserine/lurasidone being tested with Robotic Neuronavigated Transcranial Magnetic Stimulation for a one-day treatment of depression.
  • NRX-101 has received Breakthrough Therapy Designation for treating suicidal bipolar depression.
  • NRx Pharmaceuticals develops therapeutics based on its NMDA receptor platform for central nervous system disorders such as suicidal depression, chronic pain, and PTSD.
Company
NRx Pharmaceuticals Inc
Keywords
Nasdaq:NRXP, NRx Pharmaceuticals Inc